Literature DB >> 22169111

Increased plasma levels of NGAL, a marker of neutrophil activation, in patients with abdominal aortic aneurysm.

Priscila Ramos-Mozo1, Julio Madrigal-Matute, Melina Vega de Ceniga, Luis Miguel Blanco-Colio, Olivier Meilhac, Laurent Feldman, Jean-Baptiste Michel, Paula Clancy, Jonathan Golledge, Paul E Norman, Jesus Egido, José Luis Martin-Ventura.   

Abstract

OBJECTIVE: Neutrophil gelatinase-associated lipocalin (NGAL) plasma concentrations have been associated with cardiovascular diseases. We aimed to assess the association of NGAL with abdominal aortic aneurysm (AAA).
METHODS: NGAL concentrations were analyzed by Western blotting in conditioned medium of polymorphonuclear neutrophils (PMNs) from AAA patients (n=22) and controls (n=11), and also in aortic biopsies from AAA patients and healthy controls (n=10). Plasma NGAL concentrations were measured by ELISA in three groups of subjects from France (n=60), Spain (n=75) and Australia (n=100) and associated with AAA presence and growth.
RESULTS: PMNs isolated from AAA patients secreted significantly greater amounts of NGAL than PMNs from controls. Luminal thrombus released large amounts of NGAL compared to abluminal AAA thrombus, AAA wall and healthy aortic media. Plasma NGAL concentrations were significantly higher in patients with AAA than controls from France [115 (78-200) vs. 94 (72-114) ng/ml, p<0.001]. NGAL plasma concentrations in AAA patients from Spain correlated with other markers of thrombus activity (plasmin-antiplasmin complexes and D-dimer). Furthermore, a positive correlation between plasma NGAL and retrospective AAA growth (rho=0.4, p=0.01) was observed, which remained significant after adjusting for other risk factors. Plasma NGAL was only weakly associated with prospective growth in both Spanish and Australian patients.
CONCLUSIONS: NGAL is released by PMNs and by the luminal part of AAA thrombus. NGAL plasma levels were increased in AAA patients compared with healthy subjects and correlated with retrospective AAA growth. Further studies in larger subjects groups are needed to confirm the association between NGAL and AAA presence and growth.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22169111     DOI: 10.1016/j.atherosclerosis.2011.11.023

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  18 in total

1.  New Insights Into Aortic Diseases: A Report From the Third International Meeting on Aortic Diseases (IMAD3).

Authors:  Helena Kuivaniemi; Natzi Sakalihasan; Frank A Lederle; Gregory T Jones; Jean-Olivier Defraigne; Nicos Labropoulos; Victor Legrand; Jean-Baptiste Michel; Christoph Nienaber; Marc A Radermecker; John A Elefteriades
Journal:  Aorta (Stamford)       Date:  2013-06-01

Review 2.  Neutrophil Gelatinase Associated Lipocalin (NGAL) as a Biomarker. Does It Apply in Abdominal Aortic Aneurysms? A Review of Literature.

Authors:  Georgios Karaolanis; Demetrios Moris; Viktoria-Varvara Palla; Euridiki Karanikola; Chris Bakoyiannis; Sotirios Georgopoulos
Journal:  Indian J Surg       Date:  2014-05-16       Impact factor: 0.656

3.  Chronic renovascular hypertension is associated with elevated levels of neutrophil gelatinase-associated lipocalin.

Authors:  Alfonso Eirin; Monika L Gloviczki; Hui Tang; Andrew D Rule; John R Woollard; Amir Lerman; Stephen C Textor; Lilach O Lerman
Journal:  Nephrol Dial Transplant       Date:  2012-08-23       Impact factor: 5.992

4.  Deficiency of immunoglobulin E protects mice from experimental abdominal aortic aneurysms.

Authors:  Jie Li; Zhiyong Deng; Xian Zhang; Feng Liu; Chongzhe Yang; Guo-Ping Shi
Journal:  FASEB J       Date:  2020-01-02       Impact factor: 5.191

5.  Challenges of applying circulating biomarkers for abdominal aortic aneurysm progression.

Authors:  Yuan Li; Dan Yang; Yuehong Zheng
Journal:  Exp Biol Med (Maywood)       Date:  2021-02-27

6.  Plasma Levels of Monocyte Chemoattractant Protein-1, n-Terminal Fragment of Brain Natriuretic Peptide and Calcidiol Are Independently Associated with the Complexity of Coronary Artery Disease.

Authors:  Roberto Martín-Reyes; Juan Antonio Franco-Peláez; Óscar Lorenzo; María Luisa González-Casaus; Ana María Pello; Álvaro Aceña; Rocío Carda; José Luis Martín-Ventura; Luis Blanco-Colio; María Luisa Martín-Mariscal; Juan Martínez-Milla; Ricardo Villa-Bellosta; Antonio Piñero; Felipe Navarro; Jesús Egido; José Tuñón
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

Review 7.  The Abdominal Aortic Aneurysm and Intraluminal Thrombus: Current Concepts of Development and Treatment.

Authors:  Aleksandra Piechota-Polanczyk; Alicja Jozkowicz; Witold Nowak; Wolf Eilenberg; Christoph Neumayer; Tadeusz Malinski; Ihor Huk; Christine Brostjan
Journal:  Front Cardiovasc Med       Date:  2015-05-26

8.  Role of myeloperoxidase in abdominal aortic aneurysm formation: mitigation by taurine.

Authors:  Ha Won Kim; Andra L Blomkalns; Mourad Ogbi; Manesh Thomas; Daniel Gavrila; Bonnie S Neltner; Lisa A Cassis; Robert W Thompson; Robert M Weiss; Paul D Lindower; Victor M Blanco; Michael L McCormick; Alan Daugherty; Xiaoming Fu; Stanley L Hazen; Brian K Stansfield; Yuqing Huo; David J Fulton; Tapan Chatterjee; Neal L Weintraub
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-09-29       Impact factor: 4.733

Review 9.  Novel biomarkers of abdominal aortic aneurysm disease: identifying gaps and dispelling misperceptions.

Authors:  Demetrios Moris; Eleftherios Mantonakis; Efthymios Avgerinos; Marinos Makris; Chris Bakoyiannis; Emmanuel Pikoulis; Sotirios Georgopoulos
Journal:  Biomed Res Int       Date:  2014-05-20       Impact factor: 3.411

10.  Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis.

Authors:  Raffaele Serra; Raffaele Grande; Gianluca Buffone; Edoardo Scarcello; Fabio Tripodi; Pierandrea Rende; Luca Gallelli; Stefano de Franciscis
Journal:  J Pharmacol Pharmacother       Date:  2014-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.